Glaucus Proteomics Has Closed Its Doors
Glaucus Proteomics ceased its operations in October and laid off 19 employees, after a failed financing round. The Netherlands-based company had “the ink wet on a financing round of $19.5 million,” when the fourth investor, an institutional bank, pulled out at closing, said Ian Humphery Smith, Glaucus’ founder and COO, adding that “the company died quickly.” Glaucus had been developing technologies to produce protein and antibody microarrays.